<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6262033 - Remedy for diseases associated with NF-κB - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Remedy for diseases associated with NF-κB"><meta name="DC.contributor" content="Ryuichi Morishita" scheme="inventor"><meta name="DC.contributor" content="Toshio Ogiwara" scheme="inventor"><meta name="DC.contributor" content="Toshiko Sugimoto" scheme="inventor"><meta name="DC.contributor" content="Kazuhiro Maeda" scheme="inventor"><meta name="DC.contributor" content="Ikuo Kawamura" scheme="inventor"><meta name="DC.contributor" content="Toshiyuki Chiba" scheme="inventor"><meta name="DC.contributor" content="Fujisawa Pharmaceutical Co., Ltd." scheme="assignee"><meta name="DC.date" content="1996-5-10" scheme="dateSubmitted"><meta name="DC.description" content="Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-κB is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-κB, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia."><meta name="DC.date" content="2001-7-17" scheme="issued"><meta name="DC.relation" content="WO:1995012415:A1" scheme="references"><meta name="citation_reference" content="Agrawal, S. &quot;Antisense Oligonucleotides: Towards Clinical Trials&quot; TIBTECH vol. 14:376-387, Oct. 1996.*"><meta name="citation_reference" content="Golden, F. &quot;Of Mice and Men: Don&#39;t Blame the Rodents&quot; TIME, p. 44, May 18, 1998.*"><meta name="citation_reference" content="I. Kawamura et al, &quot;Intratumoral Injection of Oligonucleotides to the NFkB Binding Site Inhibits Cachexia In a Mouse Tumor Model&quot;, Gene Therapy (1999)6, 91-97."><meta name="citation_reference" content="J. Suzuki et al., &quot;Decoy Against Nuclear Factor-Kappa B Attenuates Myocardial Cell Infiltration and Arterial Neointimal Formation In Murine Cardiac Allografts&quot;, Journal: Gene Therapy,In Press."><meta name="citation_reference" content="N. Tomita et al, &quot;A Novel Strategy For Gene Therapy and Gene Regulation Analysis Using Transcription Factor Decoy Oligonucleotides&quot;, Exp. Nephrol 1997; 5:429-434."><meta name="citation_reference" content="N. Tomita et al, &quot;In Vivo Administration of a Nuclear Transcription Factor-Kappab Decoy Suppresses Experimental Crescentic Glomerulonephritis&quot;, JASN, In Press."><meta name="citation_reference" content="N. Tomita Et Al, &quot;Inhibition of TNF-alpha Induced Cytokine and Adhesion Molecule Expression In Glomerular Cells In Vitro and In Vivo By Transcription Factor Decoy For NFkB&quot;, Journal: Expreimental Nephrology, In Press."><meta name="citation_reference" content="N. Tomita Et Al, &quot;Transcription Factor Decoy For NFkB Inhibits TNF-alpha-Induced Cytokine and Adhesion Molecule Expression In Vivo&quot;, Journal: Gene Therapy, In Press."><meta name="citation_reference" content="N. Tomita Et Al, &quot;Transcription Factor Decoy For Nuclear Factor-kB Inhibits Tumor Necroses Factor-alpha-Induced Expression of Interleukin-6 and Tracellular Adhesion Molecule-1 In Endothelial Cells&quot;, Journal of Nypertension 1998, 16:993-1000."><meta name="citation_reference" content="N. Tomita Et Al, “Inhibition of TNF-α Induced Cytokine and Adhesion Molecule Expression In Glomerular Cells In Vitro and In Vivo By Transcription Factor Decoy For NFkB”, Journal: Expreimental Nephrology, In Press."><meta name="citation_reference" content="N. Tomita Et Al, “Transcription Factor Decoy For NFkB Inhibits TNF-α-Induced Cytokine and Adhesion Molecule Expression In Vivo”, Journal: Gene Therapy, In Press."><meta name="citation_reference" content="N. Tomita Et Al, “Transcription Factor Decoy For Nuclear Factor-kB Inhibits Tumor Necroses Factor-α-Induced Expression of Interleukin-6 and Tracellular Adhesion Molecule-1 In Endothelial Cells”, Journal of Nypertension 1998, 16:993-1000."><meta name="citation_reference" content="O. Yokoseki et al, &quot;CIS Element &quot;Decoy&quot; Against Nuclear Factor-Kappa B Attenuates Development of Experimental Autoimmune Myocarditis&quot;, Journal: Gene Therapy, In Press."><meta name="citation_reference" content="R. Morishita et al, &quot;Application of Transcription Factor &quot;Decoy&quot; Strategy As Means of Gene Therapy and Study of Gene Expression Cardiovascular Disease&quot;, Cir. Res., vol. 82, pp. 1023-1028 (1998)."><meta name="citation_reference" content="R. Morishita et al, &quot;In Vivo Transfection of CIS Element &quot;Decoy&quot; Against Nuclear Factor-kB Binding Site Prevents Myocardial Infarction&quot;, Nature Medicine, vol. 3, No. 8, Aug. 1997."><meta name="citation_reference" content="S. Ono et al, &quot;Decoy Administration of NF-kB Into the Subarachnoid Space For Cerebral Angiopathy&quot;, Human Gene Therapy 9;1003-1001 (May 1, 1998)."><meta name="citation_reference" content="S. Yoshimura et al, &quot;Inhibition of Intimal Hyperplasia After Balloon Injury In Rat Carotid Artery Model Using CIS-Element &quot;Decoy&quot; of Nuclear Factor-kB Binding Site As a Novel Molecular Stragety&quot;, Journal: Gene Therapy, In Press."><meta name="citation_reference" content="Stull et al. &quot;Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects&quot; Pharmaceutical Research vol. 12(4): 465-483, 1995.*"><meta name="citation_reference" content="T. Tomita Et Al, &quot;Suppressed Severity of Collagen-Induced Arthritis By In Vivo Transfection of Nuclear Factor kB Decoy Oligodeoxynucleotides As a Gene Therapy&quot;, Arthritis &amp; Rheumatism, vol. 42, No. 12, Dec. 1999."><meta name="citation_reference" content="Y. Sawa et al. &quot;A Novel Strategy For Myocardial Protection Using In Vivo Transfection of CIS Element &quot;Decoy&quot; Against NFkB Binding Site&quot;, Circulation vol. 96(9), pp. 11-281-11-285, Nov. 4, 1997."><meta name="citation_patent_number" content="US:6262033"><meta name="citation_patent_application_number" content="US:08/945,805"><link rel="canonical" href="http://www.google.com/patents/US6262033"/><meta property="og:url" content="http://www.google.com/patents/US6262033"/><meta name="title" content="Patent US6262033 - Remedy for diseases associated with NF-κB"/><meta name="description" content="Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-κB is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-κB, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia."/><meta property="og:title" content="Patent US6262033 - Remedy for diseases associated with NF-κB"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("PC_uU6-kI-PLsATzqYKABg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("DEU"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("PC_uU6-kI-PLsATzqYKABg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("DEU"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6262033?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6262033"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=W6ZVBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6262033&amp;usg=AFQjCNFaFieeMaMDCHopgSjt5WNShNoI2g" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6262033.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6262033.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6262033" style="display:none"><span itemprop="description">Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-κB is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-κB, such as ischemic diseases, inflammatory diseases, autoimmune diseases,...</span><span itemprop="url">http://www.google.com/patents/US6262033?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6262033 - Remedy for diseases associated with NF-κB</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6262033 - Remedy for diseases associated with NF-κB" title="Patent US6262033 - Remedy for diseases associated with NF-κB"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6262033 B1</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/945,805</td></tr><tr><td class="patent-bibdata-heading">PCT number</td><td class="single-patent-bibdata">PCT/JP1996/001234</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Jul 17, 2001</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">May 10, 1996</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Feb 11, 1995</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/DE69636997D1">DE69636997D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69636997T2">DE69636997T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0824918A1">EP0824918A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0824918A4">EP0824918A4</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0824918B1">EP0824918B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7871983">US7871983</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20020098162">US20020098162</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20040162250">US20040162250</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20060116344">US20060116344</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1996035430A1">WO1996035430A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08945805, </span><span class="patent-bibdata-value">945805, </span><span class="patent-bibdata-value">PCT/1996/1234, </span><span class="patent-bibdata-value">PCT/JP/1996/001234, </span><span class="patent-bibdata-value">PCT/JP/1996/01234, </span><span class="patent-bibdata-value">PCT/JP/96/001234, </span><span class="patent-bibdata-value">PCT/JP/96/01234, </span><span class="patent-bibdata-value">PCT/JP1996/001234, </span><span class="patent-bibdata-value">PCT/JP1996/01234, </span><span class="patent-bibdata-value">PCT/JP1996001234, </span><span class="patent-bibdata-value">PCT/JP199601234, </span><span class="patent-bibdata-value">PCT/JP96/001234, </span><span class="patent-bibdata-value">PCT/JP96/01234, </span><span class="patent-bibdata-value">PCT/JP96001234, </span><span class="patent-bibdata-value">PCT/JP9601234, </span><span class="patent-bibdata-value">US 6262033 B1, </span><span class="patent-bibdata-value">US 6262033B1, </span><span class="patent-bibdata-value">US-B1-6262033, </span><span class="patent-bibdata-value">US6262033 B1, </span><span class="patent-bibdata-value">US6262033B1</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Ryuichi+Morishita%22">Ryuichi Morishita</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Toshio+Ogiwara%22">Toshio Ogiwara</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Toshiko+Sugimoto%22">Toshiko Sugimoto</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Kazuhiro+Maeda%22">Kazuhiro Maeda</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Ikuo+Kawamura%22">Ikuo Kawamura</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Toshiyuki+Chiba%22">Toshiyuki Chiba</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Fujisawa+Pharmaceutical+Co.,+Ltd.%22">Fujisawa Pharmaceutical Co., Ltd.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6262033.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6262033.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6262033.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (1),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (20),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (20),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (21),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (9)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6262033&usg=AFQjCNFl7SEp6AsppkeZ-Ysxsg0ImYy-4g">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6262033&usg=AFQjCNGOU8_jVG9mC5QeGI_NsyOfBbnDJQ">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6262033B1%26KC%3DB1%26FT%3DD&usg=AFQjCNFfFUfHiccElVL8pGqtncFnB0rBEA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT91685875" lang="EN" load-source="patent-office">Remedy for diseases associated with NF-κB</invention-title></span><br><span class="patent-number">US 6262033 B1</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA72587319" lang="EN" load-source="patent-office"> <div class="abstract">Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-κB is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-κB, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(10)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6262033-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6262033-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6262033-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6262033-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6262033-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6262033-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6262033-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6262033-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6262033-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6262033-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6262033-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6262033-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6262033-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6262033-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6262033-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6262033-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6262033-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6262033-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6262033-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6262033-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(6)</span></span></div><div class="patent-text"><div mxw-id="PCLM28672428" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is: </claim-statement> <div class="claim"> <div num="1" id="US-6262033-B1-CLM-00001" class="claim">
      <div class="claim-text">1. A method for treatment of NF-κB-associated diseases which comprises administering to an animal an effective amount of a polynucleotide NF-κB chromosomal binding site decoy which antagonizes NF-κB-mediated transcription of a gene located downstream of a NF-κB binding site wherein said polynucleotide comprises the 8<sup>th </sup>through the 17<sup>th </sup>nucleotide of SEQ ID NO:1.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" id="US-6262033-B1-CLM-00002" class="claim">
      <div class="claim-text">2. The method according to claim <b>1</b> wherein the NF-κB-associated disease is selected from the group consisting of; an ischemic disease, an inflammatory disease, and an autoimmune disease.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" id="US-6262033-B1-CLM-00003" class="claim">
      <div class="claim-text">3. The method according to claim <b>1</b> wherein the NF-κB-associated disease is an ischemic disease.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" id="US-6262033-B1-CLM-00004" class="claim">
      <div class="claim-text">4. The method according to claim <b>1</b> wherein the NF-κB-associated disease is selected from the group consisting of; a reperfusion disorder in ischemic disease, aggravation of a prognosis of an organ transplantation, aggravation of a prognosis of an organ surgery, a post-PTCA restinosis.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" id="US-6262033-B1-CLM-00005" class="claim">
      <div class="claim-text">5. The method according to claim <b>1</b> wherein the NF-κB-associated disease is selected from the group consisting of; a reperfusion disorder in ischemic heart disease, aggravation of a prognosis of a heart transplantation, aggravation of a prognosis of a heart surgery, and post PTCA restinosis.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" id="US-6262033-B1-CLM-00006" class="claim">
      <div class="claim-text">6. The method according to claim <b>1</b> wherein the NF-κB-associated disease is selected from the group consisting of; a cancer metastasis a cancer invasion, and cachexia.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES54604029" lang="EN" load-source="patent-office" class="description">
    <heading>TECHNICAL FIELD</heading> <p>The present invention relates to the prevention and treatment of various diseases associated with NF-κB which is known to be a regulatory factor in the transcription of cytokines and adhesion factors. More particularly, the invention relates to an NF-κB decoy, a composition comprising said decoy for the therapy and prophylaxis of NF-κB-associated diseases, and a method for said therapy and prophylaxis.</p>
    <heading>BACKGROUND ART</heading> <p>A variety of diseases including asthma, cancers, heart diseases, autoimmune diseases, and viral infections manifest varying symptoms and signs and yet it has been suggested that either an overexpression or underexpression of one or a few proteins is a major etiologic factor in many cases. Moreover, a variety of transcriptional regulatory factors such as transcription activators and transcription inhibitors are involved in the expression of proteins. NF-κB, a substance known to be one of such transcriptional regulatory factors, is a heterodimer of p65 and p50 proteins. In the cytoplasm, NF-κB is usually present as substance binding with IκB, an inhibition factor, and thereby prevented from migrating into the nucleus. However, when a cell is stimulated by cytokines, ischemia, or reperfusion for whatever reason, IκB is phosphorylated and decomposed so that the NF-κB is activated and penetrates into the nucleus. NF-κB attaches itself to the NF-κB binding site of the chromosome and then promotes transcription of the gene located at downstreams. The gene controlled by NF-κB includes cytokines such as IL-1, IL-6, IL-8, etc. and adhesion factors such as VCAM-1, ICAM-1, etc . . .</p>
    <heading>DISCLOSURE OF THE INVENTION</heading> <p>Predicting that stimulation of the production of those cytokines and adhesion factors is causative of various morbidities such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia, the inventors of this invention did much research and found that it is a rewarding therapeutic approach to suppress expression of those genes which are activated by NF-κB by administering a decoy of the NF-κB binding site of chromosome, that is to say a compound which specifically antagonizes the binding site of chromosome to which NF-κB is conjugated. The present invention has been developed on the basis of the above finding.</p>
    <p>The present invention, therefore, provides a pharmaceutical composition comprising an NF-κB decoy as an active ingredient for the therapy and prophylaxis of various NF-κB-associated diseases and a method for said therapy and prophylaxis.</p>
    <p>The diseases in which the therapeutic/prophylactic composition of the invention is indicated are NF-κB-associated diseases, that is to say diseases caused by the unwanted activation of genes under control of the transcriptional regulatory factor NF-κB, and among such diseases can be reckoned ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia. The ischemic disease includes ischemic diseases of organs (e.g. ischemic heart diseases such as myocardial infarction, acute heart failure, chronic heart failure, etc., ischemic brain diseases such as cerebral infarction, and ischemic lung diseases such as pulmonary infarction), aggravation of the prognosis of organ transplantation or organ surgery (e.g. aggravation of the prognosis of heart transplantation, cardiac surgery, kidney transplantation, renal surgery, liver transplantation, hepatic surgery, bone marrow transplantation, skin grafting, corneal transplantation, and lung transplantation), reperfusion disorders, and post-PTCA restenosis. The inflammatory disease mentioned above includes various inflammatory diseases such as nephritis, hepatitis, arthritis, etc., acute renal failure, chronic renal failure, and arteriosclerosis, among other diseases. The autoimmune disease mentioned above includes but is not limited to rheumatism, multiple sclerosis, and Hashimoto's thyroiditis. Particularly the pharmaceutical composition containing the NF-κB decoy according to the present invention as an active ingredient is very suited for the therapy and prophylaxis of reperfusion disorders in ischemic diseases, aggravation of the prognosis of organ transplantation or organ surgery, post-PTCA restenosis, cancer metastasis and invasion, and cachexia such as weight loss following the onset of a cancer.</p>
    <p>The NF-κB decoy that can be used in the present invention may be any compound that specifically antagonizes the NF-κB binding site of the chromosome and includes but is not limited to nucleic acids and their analogs. As preferred examples of said NF-κB decoy, there can be mentioned oligonucleotides containing the nucleotide sequence of GGGATTTCCC (the sequence from the 8th through the 17th nucleotides from the 5′-end of SEQ ID NO:1 in Sequence Listing) or its complementary sequence, muteins thereof, and compounds containing any of them within the molecule. The oligonucleotides may be DNAs or RNAs, and may contain modified nucleotides and/or pseudonucleotides. Furthermore, those oligonucleotides, variants thereof, or compounds containing any of them may be single-stranded or double-stranded and linear or cyclic. The variants are those involving mutations such as substitution, addition and/or deletion of any part of the above-mentioned sequence, and mean nucleic acids specifically antagonizing the binding site of chromosome to which NF-κB is conjugated. The more preferred NF-κB decoy includes double-stranded oligonucleotides each containing one or a plurality of the above nucleotide sequence and variants thereof. The oligonucleotide which can be used in the present invention includes oligonucleotides modified so as to be less susceptible to biodegradation, such as those oligonucleotides containing the thiophosphoric diester bond available upon substitution of sulfur for the oxygen of the phosphoric diester moiety (S-oligo) and those oligonucleotides available upon substitution of a methyl phosphate group carrying no electric charge for the phosphoric diester moiety.</p>
    <p>Regarding to a technology for producing the NF-κB decoy for use in the present invention, the conventional chemical or biochemical methods for synthesis can be utilized. When a nucleic acid, for instance, is to be used as the NF-κB decoy, the methods for nucleic acid synthesis which are commonly used in genetic engineering can be employed. For example, the objective decoy oligonucleotide can be directly synthesized on a DNA synthesizer. Or a nucleic acid or its fragments, each synthesized beforehand, can be amplified by PCR or using a cloning vector or the like. Furthermore, the desired nucleic acid can be obtained by such procedures as cleavage with restriction enzymes or the like and/or ligation by means of DNA ligase or the like. In order to obtain a decoy nucleotide which is more stable within cells, the base, sugar or/and phosphoric acid moieties of the nucleic acid may be alkylated, acylated, or otherwise chemically modified.</p>
    <p>The pharmaceutical composition containing the NF-κB decoy as an active ingredient according to the present invention is not limited in form only if the active ingredient may be taken up by the cells in the affected site or the cells of the target tissue. Thus, the NF-κB decoy, either alone or in admixture with the common pharmaceutical carrier, can be administered orally, parenterally, topically or externally. The pharmaceutical composition may be provided in liquid dosage forms such as solutions, suspensions, syrups, liposomes, lotions, etc. or in solid dosage forms such as tablets, granules, powders, and capsules. Where necessary, those pharmaceutical compositions may be supplemented with various vehicles, excipients, stabilizers, lubricants, and/or other conventional pharmaceutical additives, such as lactose, citric acid, tartaric acid, stearic acid, magnesium stearate, terra alba, sucrose, corn starch, talc, gelatin, agar, pectin, peanut oil, olive oil, caccao butter, ethylene glycol, and so on.</p>
    <p>Particularly when a nucleic acid or a modification product thereof is used as the NF-κB decoy, the preferred dosage form includes those which are generally used in gene therapy, such as liposomes inclusive of membrane fusion liposomes utilizing Sendai virus and liposomes utilizing endocytosis, preparations containing cationic lipids such as Lipofectamine (Life Tech Oriental) or virosomes utilizing a retrovirus vector, adenovirus vector, or the like. Particularly preferred are membrane fusion liposomes.</p>
    <p>The structure of such a liposomal preparation may be any of a large unilamellar vesicle (LUV), a multi-lamellar vesicle (MLV), and a small unilamellar vesicle (SUV). The approximate size of vesicles may range from 200 to 1000 nm for LUV, from 400 to 3500 nm for MLV, and from 20 to 50 nm for SUV but in the case of a membrane fusion liposomal preparation using Sendai virus, for instance, MLV with a vesicular system of 200-1000 nm in diameter is preferably employed.</p>
    <p>There is no limitation on the technology for liposome production only if the decoy can be successfully entrapped in vesicles. Thus, such liposomes can be manufactured by the conventional techniques such as the reversed phase evaporation method (Szoka, F., et al: Biochim. Biophys. Acta, Vol. 601 559 (1980)), ether injection method (Deamer, D. W.: Ann. N. Y. Acad. Sci., Vol. 308 250 (1978)), and surfactant method (Brunner, J., et al: Biochim. Biophys. Acta, Vol. 455 322 (1976)), to name but a few examples.</p>
    <p>The lipid that can be used for constructing a liposomal structure includes phospholipids, cholesterol and its derivatives, and nitrogen-containing lipids but phospholipids are generally preferred. The phospholipid that can be used includes naturally-occurring phospholipids such as phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, phosphatidylethanolamine, phosphatidic acid, cardiolipin, sphingomyelin, egg yolk lecithin, soybean lecithin, lysolecithin, etc., the corresponding phospholipids hydrogenated by the conventional method, and synthetic phospholipids such as dicetyl phosphate, distearoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylethanolamine, dipalmitoylphosphatidylserine, eleostearoylphosphatidylcholine, eleostearoylphosphatidylethanolamine, eleostearoylphosphatidylserine, and so on.</p>
    <p>The lipids inclusive of phospholipids can be used each alone or in a suitable combination. By using a lipid containing a positively-charged atomic group such as ethanolamine or choline within the molecule, the binding rate of an electrically negative decoy nucleotide can be enhanced. In addition to the principal phospholipid, various compounds such as cholesterol and its derivatives, stearylamine, -tocopherol, etc., which are known as liposome additives, can be added in the manufacture of liposomes.</p>
    <p>To the resulting liposomes can be added a membrane fusion promoter such as Sendai virus, inactivated Sendai virus, a membrane fusion promoting protein purified from Sendai virus, polyethylene glycol, or the like can be added for assisting in the intracellular uptake by the cells at the affected site or of the target tissue.</p>
    <p>A typical procedure for the production of pharmaceutical liposomes is now described in detail. The above-mentioned liposome-forming substance as well as cholesterol or the like is dissolved in an organic solvent such as tetrahydrofuran, chloroform, ethanol, or the like. In a suitable vessel, the solvent is distilled off under reduced pressure to leave a film of the liposome-forming substance on the inside wall of the vessel. Then, a buffer containing the NF-κB decoy is added and the mixture is stirred. After optional addition of said membrane fusion promoter, the liposomes are isolated. The liposomes in which the NF-κB decoy has thus been entrapped are suspended in a suitable medium or a lyophilizate thereof is redispersed in a suitable medium for use in therapy. The membrane fusion promoter may be added in the interim period after isolation of the liposomes and before use.</p>
    <p>There is no limitation on the decoy content of the pharmaceutical composition containing the NF-κB decoy as an active ingredient only if the decoy is contained in amounts effective to control NF-κB-associated diseases. Thus, the decoy content can be liberally selected according to the disease to be controlled, the target site, dosage form, and dosage schedule.</p>
    <p>The pharmaceutical composition containing the NF-κB decoy as an active ingredient as provided in the above manner can be administered by various methods according to the type of disease and the kind of decoy contained. Taking ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis or invasion, and cachexia as examples, the composition can be infused intravascularly, applied directly to the affected area, injected into the lesion, or administered into the regional blood vessel in the affected region. As a further specific example, when PTCA is performed for infarction of an organ, the pharmaceutical composition can be administered into the local blood vessel concurrently with the operation or pre- and postoperatively. For organ transplantation, the graft material can be previously treated with the composition of the invention. Furthermore, in the treatment of osteoarthritis or rheumatism, the composition can be directly injected into the joint.</p>
    <p>The dosage of the NF-κB decoy is selected with reference to the patient's age and other factors, type of disease, the kind of decoy used, etc. but for intravascular, intramuscular, or intraarticular administration, for instance, a unit dose of 10-10,000 nmoles can generally be administered once to a few times daily.</p>
    <heading>BEST MODE FOR CARRYING OUT THE INVENTION</heading> <p>The following examples are intended to describe the present invention in further detail.</p>
    <heading>EXAMPLE 1</heading> <p>Synthesis of an NF-κB decoy (decoy oligonucleotide)</p>
    <p>On a DNA synthesizer, an NF-κB decoy oligonucleotide and a scrambled decoy oligonucleotide (an oligonucleotide having the same base composition as the NF-κB decoy oligonucleotide but a randomized sequence), the nucleotide sequences of which are shown below, were respectively synthesized from S-oligonucleotides. Those nucleotides were heated at 80° C. for 30 minutes and then allowed to cool to room temperature over 2 hours to provide double-stranded DNAs.</p>
    <p>NF-κB decoy oligonucleotide</p>
    <p>CCTTGAAGGGATTTCCCTCC (SEQ ID NO:1)</p>
    <p>GGAACTTCCCTAAAGGGAGG (SEQ ID NO:3)</p>
    <p>Scrambled decoy oligonucleotide</p>
    <p>TTGCCGTACCTGACTTAGCC (SEQ ID NO:2)</p>
    <p>AACGGCATGGACTGAATCGG (SEQ ID NO:4)</p>
    <heading>EXAMPLE 2</heading> <heading>Production of Liposomal Preparations</heading> <p>Phosphatidylserine, phosphatidylcholine, and cholesterol, provided in a weight ratio of 1:4.8:2 (a total of 10 mg), were dissolved in tetrahydrofuran. Using a rotary evaporator, the tetrahydrofuran was removed from the lipid solution to leave the lipid in the form of a film adherent to the flask wall. To this was added 200 ml of saline (BSS; 139 mM NaCl, 5.4 mM KCl, 10 mM Tris-HCl, pH7.6) containing the NF-κB decoy oligonucleotide (0.7 mg) prepared in Example 1 and the mixture was stirred and sonicated under the usual conditions to provide a suspension of liposomes containing the NF-κB decoy oligonucleotide. This suspension of liposomevesicles (0.5 ml, lipid content 10 mg) was mixed with purified Sendai virus (Z strain, 10000 hemaglutinating units) exposed to UV radiation (110 erg/mm<sup>2</sup>/sec) 3 minutes before use and the mixture was made up to 4 ml with BSS. This mixture was held at 4° C. for 5 minutes and, then, subjected to gentle shaking at 37° C. for 30 minutes. After the Sendai virus not bound to the liposomes was removed by sucrose density gradient centrifugation, the uppermost layer was separated and its concentration was adjusted with BSS to provide a liposomal preparation containing 8 μM NF-κB decoy oligonucleotide as entrapped. A liposomal preparation was similarly produced using the scrambled decoy oligonucleotide of Example 1 in lieu of the NF-κB decoy oligonucleotide.</p>
    <heading>EXAMPLE 3</heading> <heading>A Reperfusion Model Experiment</heading> <p>(1) Method</p>
    <p>After 9˜10-week-old SD rats were anesthetized with pentobarbital sodium, a cannula was inserted into the left carotid artery adjacent to the airway and indwelled near the aortic valve of the heart (close to the ostium of the coronary artery). In addition, the trachea was cannulated and the animal was placed on supportive respiration by connecting the tracheal cannula to an artificial respirator. Thereafter, a left intercostal incision was made and the left descending anterior branch of the rat heart was ligated to produce ischemia. After 30 minutes, the ligating suture was cut to start reperfusion. Immediately thereafter, 1.5 ml/rat of the liposomally entrapped NF-κB decoy nucleotide or scrambled decoy nucleotide prepared in Example 2 was administered via the cannula indwelled close to the ostium of the coronary artery. After the chest was closed, the trachea was also sutured and the animal was kept alive. After 24 hours, the rat was reanesthetized and the heart was enucleated and washed with saline. The ventricle of the rat heart was sliced into six sections which were stained with tetrazolium chloride (TTC). The six sections were respectively photographed and subjected to image analysis. The infarcted area was calculated by means of the following equation.</p>
    <p>
      <maths> <formula-text>Infarction rate (%)=the sum of infarct areas of 6 sections/the sum of areas of 6 sections×100</formula-text> </maths> </p>
    <p>Statistical analysis was made by multiple comparison (ANOVA).</p>
    <p>(2) Results</p>
    <p>The results are presented in Table 1. In the untreated control group and the scrambled decoy treatment group, myocardial infarcts were found in approximately equal degrees. In the group given the NF-κB decoy nucleotide, the infarct was suppressed to 19% with a significant difference (P&lt;0.01) from the untreated group and the scrambled decoy group.</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup cols="4" colsep="0" rowsep="0" align="left"> <colspec colname="OFFSET" align="left" colwidth="56PT"> </colspec> <colspec colname="1" align="center" colwidth="70PT"> </colspec> <colspec colname="2" align="center" colwidth="35PT"> </colspec> <colspec colname="3" align="center" colwidth="56PT"> </colspec> <thead valign="bottom"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td namest="OFFSET" nameend="3" morerows="0" rowsep="1" valign="top" class="description-td" colspan="4">TABLE 1</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td namest="OFFSET" nameend="3" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="4"> </td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">NF-κB decoy</td>
                <td morerows="0" valign="top" class="description-td">Scrambled</td>
                <td morerows="0" valign="top" class="description-td"> </td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">nucleotide</td>
                <td morerows="0" valign="top" class="description-td">decoy</td>
                <td morerows="0" valign="top" class="description-td">Untreated</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">group</td>
                <td morerows="0" valign="top" class="description-td">group</td>
                <td morerows="0" valign="top" class="description-td">group</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td namest="OFFSET" nameend="3" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="4"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup cols="5" colsep="0" rowsep="0" align="left"> <colspec colname="OFFSET" align="left" colwidth="14PT"> </colspec> <colspec colname="1" align="left" colwidth="42PT"> </colspec> <colspec colname="2" align="center" colwidth="70PT"> </colspec> <colspec colname="3" align="center" colwidth="35PT"> </colspec> <colspec colname="4" align="center" colwidth="56PT"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">Myocardial</td>
                <td morerows="0" valign="top" class="description-td">19 2%</td>
                <td morerows="0" valign="top" class="description-td">23 1%</td>
                <td morerows="0" valign="top" class="description-td">28 1%</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">infarct area/</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td morerows="0" valign="top" class="description-td">total area</td>
              </tr> <tr class="description-tr"> <td morerows="0" valign="top" class="description-td"> </td>
                <td namest="OFFSET" nameend="4" morerows="0" rowsep="1" valign="top" align="center" class="description-td" colspan="5"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>A similar inhibitory effect was found when the liposomes were administered immediately before induction of infarction.</p>
    <heading>EXAMPLE 4</heading> <heading>Inhibition of Cancer Metastasis</heading> <p>(1) Method</p>
    <p>To 7-week-old female mice of the C57BL/6 strain, 1×10<sup>4 </sup>murine reticulum cell sarcoma M5076 cells were administered intravenously and 24 hours later 0.2 ml (6 nmoles) of an NF-κB decoy nucleotide prepared in the same manner as Example 2 was administered intravenously. A control group received 0.2 ml of saline in the same manner. On day 14 after intravenous administration of M5076, the animal was autopsied and the number of tumor nodules on the surface of the liver was counted under the stereoscopic microscope. Each group consisted of 10 mice. For statistical analyses, Kruskal-Wallis test and Dunnett's multiple comparison were used.</p>
    <p>(2) Results</p>
    <p>Whereas the mean number of tumor nodules in the control group was 166 with a median value of 173 (116-198), the NF-κB decoy treatment group showed a mean number of 29 and a median number of 27 (19-54). Thus, between the NF-κB decoy treatment group and the control group, a significant difference was found at the 1% level.</p>
    <heading>EXAMPLE 5</heading> <heading>Inhibition of Cachexia</heading> <p>(1) Method</p>
    <p>Using 7-week-old male BALB/c mice, a 2 mm cubic tumor mass of murine colon cancer line Colon 26 was transplanted subdermally. Beginning day 7 after transplantation, 0.2 ml (6 nmoles) of the NF-κB decoy or the scrambled decoy was administered into the tumor mass and the body weight and tumor weight were serially determined. The animal was autopsied on day 13 and the epididymal fat and gastrocnemius muscle were isolated and weighed. Furthermore, the wet carcass weight exclusive of all the remaining organs and tumor was determined. The tumor weight was calculated from the major and minor diameters of each tumor mass by means of the following equation.</p>
    <p>
      <maths> <formula-text>Tumor weight (mg)=major diameter×minor diameter<sup>2</sup>/2</formula-text> </maths> </p>
    <p>Each group consisted of 10 mice. Statistical analyses were made by ANOVA in one-way layout and Dunnett's multiple comparison.</p>
    <p>(2) Results</p>
    <p>In the tumor-bearing group, growth of the tumor resulted in significant decreases in body weight, epididymal fat weight, gastrocnemius muscle weight, and wet carcass weight. In the NF-κB decoy group, improvements were obtained, amounting to 47% for body weight, 42% for epididymal fat weight, 60% for gastrocnemius weight, and 52% for wet carcass weight. However,</p>
    <p>
      <sequence-cwu id="SEQLST-1"> <sequence-list-new-rules> <s100> <s160>4</s160> </s100> <s200> <s210>1</s210> <s211>20</s211> <s212>DNA</s212> <s213>Artificial Sequence</s213> <s220> <s223>Description of Artificial SequenceSynthetic
      DNA</s223> </s220> </s200> <s400> 1
ccttgaaggg atttccctcc                                                 20</s400> <s200> <s210>2</s210> <s211>20</s211> <s212>DNA</s212> <s213>Artificial Sequence</s213> <s220> <s223>Description of Artificial SequenceSynthetic
      DNA</s223> </s220> </s200> <s400> 2
ttgccgtacc tgacttagcc                                                 20</s400> <s200> <s210>3</s210> <s211>20</s211> <s212>DNA</s212> <s213>Artificial Sequence</s213> <s220> <s223>Description of Artificial SequenceSynthetic
      DNA</s223> </s220> </s200> <s400> 3
ggaacttccc taaagggagg                                                 20</s400> <s200> <s210>4</s210> <s211>20</s211> <s212>DNA</s212> <s213>Artificial Sequence</s213> <s220> <s223>Description of Artificial SequenceSynthetic
      DNA</s223> </s220> </s200> <s400> 4
aacggcatgg actgaatcgg                                                 20</s400> </sequence-list-new-rules> </sequence-cwu> </p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1995012415A1?cl=en">WO1995012415A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 7, 1994</td><td class="patent-data-table-td patent-date-value">May 11, 1995</td><td class="patent-data-table-td ">Isis Pharmaceuticals Inc</td><td class="patent-data-table-td ">Modulation of vascular cell adhesion molecule expression through novel oligonucleotide interactions</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Agrawal, S. "<a href='http://scholar.google.com/scholar?q="Antisense+Oligonucleotides%3A+Towards+Clinical+Trials"'>Antisense Oligonucleotides: Towards Clinical Trials</a>" TIBTECH vol. 14:376-387, Oct. 1996.*</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Golden, F. "<a href='http://scholar.google.com/scholar?q="Of+Mice+and+Men%3A+Don%27t+Blame+the+Rodents"'>Of Mice and Men: Don't Blame the Rodents</a>" TIME, p. 44, May 18, 1998.*</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">I. Kawamura et al, "<a href='http://scholar.google.com/scholar?q="Intratumoral+Injection+of+Oligonucleotides+to+the+NFkB+Binding+Site+Inhibits+Cachexia+In+a+Mouse+Tumor+Model"'>Intratumoral Injection of Oligonucleotides to the NFkB Binding Site Inhibits Cachexia In a Mouse Tumor Model</a>", Gene Therapy (1999)6, 91-97.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. Suzuki et al., "<a href='http://scholar.google.com/scholar?q="Decoy+Against+Nuclear+Factor-Kappa+B+Attenuates+Myocardial+Cell+Infiltration+and+Arterial+Neointimal+Formation+In+Murine+Cardiac+Allografts"'>Decoy Against Nuclear Factor-Kappa B Attenuates Myocardial Cell Infiltration and Arterial Neointimal Formation In Murine Cardiac Allografts</a>", Journal: Gene Therapy,In Press.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">N. Tomita et al, "<a href='http://scholar.google.com/scholar?q="A+Novel+Strategy+For+Gene+Therapy+and+Gene+Regulation+Analysis+Using+Transcription+Factor+Decoy+Oligonucleotides"'>A Novel Strategy For Gene Therapy and Gene Regulation Analysis Using Transcription Factor Decoy Oligonucleotides</a>", Exp. Nephrol 1997; 5:429-434.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">N. Tomita et al, "<a href='http://scholar.google.com/scholar?q="In+Vivo+Administration+of+a+Nuclear+Transcription+Factor-Kappab+Decoy+Suppresses+Experimental+Crescentic+Glomerulonephritis"'>In Vivo Administration of a Nuclear Transcription Factor-Kappab Decoy Suppresses Experimental Crescentic Glomerulonephritis</a>", JASN, In Press.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">N. Tomita Et Al, "<a href='http://scholar.google.com/scholar?q="Inhibition+of+TNF-alpha+Induced+Cytokine+and+Adhesion+Molecule+Expression+In+Glomerular+Cells+In+Vitro+and+In+Vivo+By+Transcription+Factor+Decoy+For+NFkB"'>Inhibition of TNF-alpha Induced Cytokine and Adhesion Molecule Expression In Glomerular Cells In Vitro and In Vivo By Transcription Factor Decoy For NFkB</a>", Journal: Expreimental Nephrology, In Press.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">N. Tomita Et Al, "<a href='http://scholar.google.com/scholar?q="Transcription+Factor+Decoy+For+NFkB+Inhibits+TNF-alpha-Induced+Cytokine+and+Adhesion+Molecule+Expression+In+Vivo"'>Transcription Factor Decoy For NFkB Inhibits TNF-alpha-Induced Cytokine and Adhesion Molecule Expression In Vivo</a>", Journal: Gene Therapy, In Press.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">N. Tomita Et Al, "<a href='http://scholar.google.com/scholar?q="Transcription+Factor+Decoy+For+Nuclear+Factor-kB+Inhibits+Tumor+Necroses+Factor-alpha-Induced+Expression+of+Interleukin-6+and+Tracellular+Adhesion+Molecule-1+In+Endothelial+Cells"'>Transcription Factor Decoy For Nuclear Factor-kB Inhibits Tumor Necroses Factor-alpha-Induced Expression of Interleukin-6 and Tracellular Adhesion Molecule-1 In Endothelial Cells</a>", Journal of Nypertension 1998, 16:993-1000.</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">N. Tomita Et Al, "<a href='http://scholar.google.com/scholar?q="Inhibition+of+TNF-%CE%B1+Induced+Cytokine+and+Adhesion+Molecule+Expression+In+Glomerular+Cells+In+Vitro+and+In+Vivo+By+Transcription+Factor+Decoy+For+NFkB"'>Inhibition of TNF-α Induced Cytokine and Adhesion Molecule Expression In Glomerular Cells In Vitro and In Vivo By Transcription Factor Decoy For NFkB</a>", Journal: Expreimental Nephrology, In Press.</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">N. Tomita Et Al, "<a href='http://scholar.google.com/scholar?q="Transcription+Factor+Decoy+For+NFkB+Inhibits+TNF-%CE%B1-Induced+Cytokine+and+Adhesion+Molecule+Expression+In+Vivo"'>Transcription Factor Decoy For NFkB Inhibits TNF-α-Induced Cytokine and Adhesion Molecule Expression In Vivo</a>", Journal: Gene Therapy, In Press.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">N. Tomita Et Al, "<a href='http://scholar.google.com/scholar?q="Transcription+Factor+Decoy+For+Nuclear+Factor-kB+Inhibits+Tumor+Necroses+Factor-%CE%B1-Induced+Expression+of+Interleukin-6+and+Tracellular+Adhesion+Molecule-1+In+Endothelial+Cells"'>Transcription Factor Decoy For Nuclear Factor-kB Inhibits Tumor Necroses Factor-α-Induced Expression of Interleukin-6 and Tracellular Adhesion Molecule-1 In Endothelial Cells</a>", Journal of Nypertension 1998, 16:993-1000.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">O. Yokoseki et al, "<a href='http://scholar.google.com/scholar?q="CIS+Element+%22Decoy%22+Against+Nuclear+Factor-Kappa+B+Attenuates+Development+of+Experimental+Autoimmune+Myocarditis"'>CIS Element "Decoy" Against Nuclear Factor-Kappa B Attenuates Development of Experimental Autoimmune Myocarditis</a>", Journal: Gene Therapy, In Press.</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">R. Morishita et al, "<a href='http://scholar.google.com/scholar?q="Application+of+Transcription+Factor+%22Decoy%22+Strategy+As+Means+of+Gene+Therapy+and+Study+of+Gene+Expression+Cardiovascular+Disease"'>Application of Transcription Factor "Decoy" Strategy As Means of Gene Therapy and Study of Gene Expression Cardiovascular Disease</a>", Cir. Res., vol. 82, pp. 1023-1028 (1998).</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">R. Morishita et al, "<a href='http://scholar.google.com/scholar?q="In+Vivo+Transfection+of+CIS+Element+%22Decoy%22+Against+Nuclear+Factor-kB+Binding+Site+Prevents+Myocardial+Infarction"'>In Vivo Transfection of CIS Element "Decoy" Against Nuclear Factor-kB Binding Site Prevents Myocardial Infarction</a>", Nature Medicine, vol. 3, No. 8, Aug. 1997.</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">S. Ono et al, "<a href='http://scholar.google.com/scholar?q="Decoy+Administration+of+NF-kB+Into+the+Subarachnoid+Space+For+Cerebral+Angiopathy"'>Decoy Administration of NF-kB Into the Subarachnoid Space For Cerebral Angiopathy</a>", Human Gene Therapy 9;1003-1001 (May 1, 1998).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">S. Yoshimura et al, "<a href='http://scholar.google.com/scholar?q="Inhibition+of+Intimal+Hyperplasia+After+Balloon+Injury+In+Rat+Carotid+Artery+Model+Using+CIS-Element+%22Decoy%22+of+Nuclear+Factor-kB+Binding+Site+As+a+Novel+Molecular+Stragety"'>Inhibition of Intimal Hyperplasia After Balloon Injury In Rat Carotid Artery Model Using CIS-Element "Decoy" of Nuclear Factor-kB Binding Site As a Novel Molecular Stragety</a>", Journal: Gene Therapy, In Press.</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Stull et al. "<a href='http://scholar.google.com/scholar?q="Antigene%2C+Ribozyme+and+Aptamer+Nucleic+Acid+Drugs%3A+Progress+and+Prospects"'>Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects</a>" Pharmaceutical Research vol. 12(4): 465-483, 1995.*</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">T. Tomita Et Al, "<a href='http://scholar.google.com/scholar?q="Suppressed+Severity+of+Collagen-Induced+Arthritis+By+In+Vivo+Transfection+of+Nuclear+Factor+kB+Decoy+Oligodeoxynucleotides+As+a+Gene+Therapy"'>Suppressed Severity of Collagen-Induced Arthritis By In Vivo Transfection of Nuclear Factor kB Decoy Oligodeoxynucleotides As a Gene Therapy</a>", Arthritis &amp; Rheumatism, vol. 42, No. 12, Dec. 1999.</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Y. Sawa et al. "<a href='http://scholar.google.com/scholar?q="A+Novel+Strategy+For+Myocardial+Protection+Using+In+Vivo+Transfection+of+CIS+Element+%22Decoy%22+Against+NFkB+Binding+Site"'>A Novel Strategy For Myocardial Protection Using In Vivo Transfection of CIS Element "Decoy" Against NFkB Binding Site</a>", Circulation vol. 96(9), pp. 11-281-11-285, Nov. 4, 1997.</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6911541">US6911541</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2001</td><td class="patent-data-table-td patent-date-value">Jun 28, 2005</td><td class="patent-data-table-td ">North Carolina State University</td><td class="patent-data-table-td ">Nucleotide sequences for use in reducing nicotine concentration in tobacco</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7189570">US7189570</a></td><td class="patent-data-table-td patent-date-value">Nov 7, 2001</td><td class="patent-data-table-td patent-date-value">Mar 13, 2007</td><td class="patent-data-table-td ">North Carolina State University</td><td class="patent-data-table-td ">Putrescine-n-methyltransferase promoter</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7192771">US7192771</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2001</td><td class="patent-data-table-td patent-date-value">Mar 20, 2007</td><td class="patent-data-table-td ">North Carolina State University</td><td class="patent-data-table-td ">Plant promoter sequence</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7378509">US7378509</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 2, 2004</td><td class="patent-data-table-td patent-date-value">May 27, 2008</td><td class="patent-data-table-td ">Anesiva, Inc.</td><td class="patent-data-table-td ">Bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers; for inflammatory, immune or autoimmune disease, cancer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7482158">US7482158</a></td><td class="patent-data-table-td patent-date-value">Jun 30, 2005</td><td class="patent-data-table-td patent-date-value">Jan 27, 2009</td><td class="patent-data-table-td ">Mathison Brian H</td><td class="patent-data-table-td ">Composite polynucleic acid therapeutics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7524830">US7524830</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 12, 2006</td><td class="patent-data-table-td patent-date-value">Apr 28, 2009</td><td class="patent-data-table-td ">Anges Mg, Inc.</td><td class="patent-data-table-td ">Decoy-containing pharmaceutical compositions and method of using the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7585848">US7585848</a></td><td class="patent-data-table-td patent-date-value">Jan 11, 2005</td><td class="patent-data-table-td patent-date-value">Sep 8, 2009</td><td class="patent-data-table-td ">Rush University Medical Center</td><td class="patent-data-table-td ">Administration of NF- kappa B inhibitor into intervertebral disc to treat intervertebral disc degeneration, wherein NF- kappa B inhibitor is selected from decoy oligonucleotide capable of binding to and acting on DNA binding site of NF- kappa B, antisense NF- kappa B nucleic acid, and NF- kappa B siRNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7871983">US7871983</a></td><td class="patent-data-table-td patent-date-value">Feb 14, 2003</td><td class="patent-data-table-td patent-date-value">Jan 18, 2011</td><td class="patent-data-table-td ">Anges Mg Inc.</td><td class="patent-data-table-td ">For therapy and prophylaxis of ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7897751">US7897751</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 19, 2007</td><td class="patent-data-table-td patent-date-value">Mar 1, 2011</td><td class="patent-data-table-td ">Hosokawa Micron Corporation</td><td class="patent-data-table-td ">Pharmaceutical preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7943591">US7943591</a></td><td class="patent-data-table-td patent-date-value">May 12, 2008</td><td class="patent-data-table-td patent-date-value">May 17, 2011</td><td class="patent-data-table-td ">Adynxx, Inc.</td><td class="patent-data-table-td ">Gene expression and pain</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8034619">US8034619</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 20, 2004</td><td class="patent-data-table-td patent-date-value">Oct 11, 2011</td><td class="patent-data-table-td ">University Of Cincinnati</td><td class="patent-data-table-td ">Polyamides for nucleic acid delivery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8067384">US8067384</a></td><td class="patent-data-table-td patent-date-value">Oct 20, 2005</td><td class="patent-data-table-td patent-date-value">Nov 29, 2011</td><td class="patent-data-table-td ">Anges Mg, Inc.</td><td class="patent-data-table-td ">Chimera (double) decoy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8067388">US8067388</a></td><td class="patent-data-table-td patent-date-value">Jan 7, 2009</td><td class="patent-data-table-td patent-date-value">Nov 29, 2011</td><td class="patent-data-table-td ">Anges Mg, Inc.</td><td class="patent-data-table-td ">Decoy-containing pharmaceutical compositions and method of using the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8093225">US8093225</a></td><td class="patent-data-table-td patent-date-value">Mar 15, 2011</td><td class="patent-data-table-td patent-date-value">Jan 10, 2012</td><td class="patent-data-table-td ">Adynxx, Inc.</td><td class="patent-data-table-td ">Gene expression and pain</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8236280">US8236280</a></td><td class="patent-data-table-td patent-date-value">Mar 10, 2011</td><td class="patent-data-table-td patent-date-value">Aug 7, 2012</td><td class="patent-data-table-td ">University Of Cincinnati</td><td class="patent-data-table-td ">Polyamides for nucleic acid delivery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8501478">US8501478</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 2008</td><td class="patent-data-table-td patent-date-value">Aug 6, 2013</td><td class="patent-data-table-td ">University Of Cincinnati</td><td class="patent-data-table-td ">Trehalose click polymers for delivery of biologically active molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8685368">US8685368</a></td><td class="patent-data-table-td patent-date-value">Jul 3, 2012</td><td class="patent-data-table-td patent-date-value">Apr 1, 2014</td><td class="patent-data-table-td ">Theresa M. Reineke</td><td class="patent-data-table-td ">Polyamides for nucleic acid delivery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8741864">US8741864</a></td><td class="patent-data-table-td patent-date-value">Dec 9, 2011</td><td class="patent-data-table-td patent-date-value">Jun 3, 2014</td><td class="patent-data-table-td ">Adynxx, Inc</td><td class="patent-data-table-td ">Gene expression and pain</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006034433A2?cl=en">WO2006034433A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 21, 2005</td><td class="patent-data-table-td patent-date-value">Mar 30, 2006</td><td class="patent-data-table-td ">Corgentech Inc</td><td class="patent-data-table-td ">Delivery of polynucleotides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006086105A2?cl=en">WO2006086105A2</a></td><td class="patent-data-table-td patent-date-value">Jan 11, 2006</td><td class="patent-data-table-td patent-date-value">Aug 17, 2006</td><td class="patent-data-table-td ">Anges Mg Inc</td><td class="patent-data-table-td ">Methods and compositions for treating intervertebral disc disorders</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S04400R">514/44.00R</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S024100">536/24.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S375000">435/375</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S455000">435/455</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S377000">435/377</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S024500">536/24.5</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S006110">435/6.11</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S006170">435/6.17</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0048000000">A61K48/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038000000">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031000000">A61K31/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015113000">C12N15/113</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N15/113">C12N15/113</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/00">A61K31/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/315">C12N2310/315</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/13">C12N2310/13</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K48/005">A61K48/005</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=W6ZVBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/00">A61K38/00</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K48/00D</span>, <span class="nested-value">A61K31/00</span>, <span class="nested-value">C12N15/113</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Dec 19, 2012</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 12, 2009</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 29, 2008</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">May 23, 2006</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIM 1 IS DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 2-6, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE. NEW CLAIM 7 IS ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 17, 2005</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 23, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ANGES MG INC., JAPAN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FUJISAWA PHARMACEUTICAL CO., LTD.;REEL/FRAME:015400/0489</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20020527</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ANGES MG INC. 4-2, SHINSENRIHIGASHIMACHI 1-CHOMETO</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FUJISAWA PHARMACEUTICAL CO., LTD. /AR;REEL/FRAME:015400/0489</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 26, 2002</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20020104</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 1, 2002</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 14, 1998</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">FUJISAWA PHARMACEUTICAL CO., LTD., JAPAN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORISHITA, RYUICHI;OGIWARA, TOSHIO;SUGIMOTO, TOSHIKO;ANDOTHERS;REEL/FRAME:009311/0266</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19971105</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U1FbJuvtehkReft2xMaciQHZ24NXA\u0026id=W6ZVBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U3c1ehTKN3hdWA7nM-I0fYHc-hj2w\u0026id=W6ZVBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U29X6tJpl247kYFsY4b-LMEgPioHw","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Remedy_for_diseases_associated_with_NF.pdf?id=W6ZVBAABERAJ\u0026output=pdf\u0026sig=ACfU3U2bKqz-xzpaFm81bDCZHJaLxjMiDA"},"sample_url":"http://www.google.com/patents/reader?id=W6ZVBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>